<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03345004</url>
  </required_header>
  <id_info>
    <org_study_id>DIAGNODE-2 (D/P2/17/6)</org_study_id>
    <secondary_id>2017-001861-25</secondary_id>
    <nct_id>NCT03345004</nct_id>
  </id_info>
  <brief_title>GAD-Alum (Diamyd) Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes</brief_title>
  <official_title>A Phase IIb, 2-Arm, Randomized, Double-blind, Placebo-Controlled, Multicentre Study to Optimize Diamyd® Therapy Administered Into Lymph Nodes Combined With Oral Vitamin D to Investigate the Impact on the Progression of Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Diamyd Medical AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Diamyd Medical AB</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of DIAGNODE-2 is to evaluate the efficacy of Diamyd compared to Placebo, upon
      administration directly into a lymph node in combination with an oral vitamin D/Placebo
      regimen, in terms of preserving endogenous insulin secretion as measured by C-peptide.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a 2-arm, randomized, double-blind, placebo-controlled, multicenter, clinical
      trial. Eligible patients will receive injections of Diamyd/placebo into an inguinal lymph
      gland at three occasions, with one month intervals in combination with an oral vitamin
      D/placebo regimen (starting 1 month ahead of injections) during 4 months. All patients will
      continue to receive intensive insulin treatment from their personal physicians during the
      whole study period. The patients will be followed in a blinded manner for a total of 15
      months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 20, 2017</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study is a 2-arm, randomized, double-blind, placebo-controlled, multicenter, clinical trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in stimulated C-peptide during a MMTT</measure>
    <time_frame>Baseline and 15 months</time_frame>
    <description>Change in C-peptide (Area Under the Curve [AUC]mean 0-120 min) during a Mixed Meal Tolerance Test (MMTT) between baseline to 15 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stimulated maximum C-peptide above 0.2 nmol/L</measure>
    <time_frame>15 months</time_frame>
    <description>• Proportion of patients with a stimulated maximum C-peptide level above 0.2 nmol/L (0.6 ng/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stimulated C-peptide above 0.2 nmol/L at 90 min</measure>
    <time_frame>15 months</time_frame>
    <description>• Proportion of patients with a stimulated 90min C-peptide level above 0.2 nmol/L (0.6 ng/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Change in maximum C-peptide</measure>
    <time_frame>Baseline and 15 months</time_frame>
    <description>• Change in maximum C-peptide during MMTT (nmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-peptide levels during a MMTT</measure>
    <time_frame>15 months</time_frame>
    <description>• C-peptide measured at 30, 60, 90, and 120 minutes during MMTT (nmol/L) at 15 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Change in Fasting C-peptide</measure>
    <time_frame>Baseline and 15 months</time_frame>
    <description>• Change in Fasting C-peptide (nmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>Baseline and 15 months</time_frame>
    <description>• Change in HbA1c (mmol/mol)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in insulin consumption</measure>
    <time_frame>Baseline and 15 months</time_frame>
    <description>• Change in daily exogenous insulin consumption (IU)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in IDAA1c</measure>
    <time_frame>Baseline and 15 months</time_frame>
    <description>• Change in insulin-dose-adjusted HbA1c (IDAA1c)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with IDAA1c ≤ 9</measure>
    <time_frame>15 months</time_frame>
    <description>• Proportion of patients with IDAA1c ≤ 9</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in glycemic variability/fluctuations</measure>
    <time_frame>Screening and 15 months</time_frame>
    <description>• Change in glycemic variability/fluctuations (evaluated from data from continuous glucose monitoring FreeStyle LibrePro, FGM) over 14 day period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hypoglycemias</measure>
    <time_frame>Baseline and 15 months</time_frame>
    <description>• Number of self-reported episodes of severe hypoglycemia (Severe hypoglycemia defined as needing help from others and/or seizures and/or unconscious) (counts)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients having at least 1 severe hypoglycemic event</measure>
    <time_frame>Baseline and 15 months</time_frame>
    <description>• Number of patients having at least 1 severe hypoglycemic event (counts)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Rate of hypoglycemic events</measure>
    <time_frame>Baseline and 15 months</time_frame>
    <description>• Change in Rate of hypoglycemic events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Injection site reactions</measure>
    <time_frame>15 months</time_frame>
    <description>• Injection site reactions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>15 months</time_frame>
    <description>• Occurrence of AEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory analysis of safety parameters</measure>
    <time_frame>15 months</time_frame>
    <description>• Laboratory measurements (hematology and clinical chemistry)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine analysis</measure>
    <time_frame>15 months</time_frame>
    <description>• Urine analysis (microalbuminuria, creatinine)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examination</measure>
    <time_frame>15 months</time_frame>
    <description>• Physical examinations, including neurological assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GAD65A titer</measure>
    <time_frame>15 months</time_frame>
    <description>• GAD65A titer (IU/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>15 months</time_frame>
    <description>• Vital signs (blood pressure) (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total serum Immunoglobulin E</measure>
    <time_frame>15 months</time_frame>
    <description>• Total serum Immunoglobulin E (IgE) (IU/ml).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of serum autoantibodies</measure>
    <time_frame>15 months</time_frame>
    <description>• Concentrations of serum autoantibodies towards GAD65 and IA 2 (IU/ml).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of serum autoantibodies isotypes</measure>
    <time_frame>15 months</time_frame>
    <description>• Concentrations of serum autoantibody isotypes towards GAD65 (IU/ml).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine secretion patterns of PBMCs</measure>
    <time_frame>15 months</time_frame>
    <description>• Secretion of cytokines interleukin (IL)-1, IL-2, IL-5, IL-13, IL-10, IL-17, interferon (IFN)γ, and tumour necrosis factor (TNF)α by peripheral blood mononuclear cells (PBMCs) upon stimulation with GAD65.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of PMBCs secreting specific cytokines</measure>
    <time_frame>15 months</time_frame>
    <description>• Number of PBMCs secreting IL-10, IL-4 and/or IFNγ upon stimulation with GAD65 measured by enzyme linked immunosorbent spot forming cell assay (ELISPOT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proliferation of PBMCs</measure>
    <time_frame>15 months</time_frame>
    <description>• Proliferation of PBMCs upon stimulation with GAD65.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Flow cytometric analysis of PBMC subsets</measure>
    <time_frame>15 months</time_frame>
    <description>• FACS analysis of PBMC subsets.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory immunological characterization</measure>
    <time_frame>15 months</time_frame>
    <description>• Further exploratory immunological characterization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life</measure>
    <time_frame>Baseline and 15 months</time_frame>
    <description>• Change in QoL as measured by questionnaire EQ-5D-5L between baseline and Month 15.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality adjusted life years</measure>
    <time_frame>15 months</time_frame>
    <description>• Quality adjusted life years (QALYs) based on the EQ-5D-5L questionnaire.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <condition>Diabetes Mellitus</condition>
  <condition>Autoimmune Diseases</condition>
  <condition>Metabolic Disease</condition>
  <condition>Glucose Metabolism Disorders</condition>
  <condition>Immune System Diseases</condition>
  <condition>Endocrine System Diseases</condition>
  <condition>Juvenile Diabetes</condition>
  <condition>Insulin Dependent Diabetes</condition>
  <condition>Autoimmune Diabetes</condition>
  <condition>Vitamin D</condition>
  <condition>Physiological Effects of Drugs</condition>
  <arm_group>
    <arm_group_label>Active arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be assigned to receive i) three (3) intralymphatic injections with 4µg Diamyd (GAD-alum) on Days 30, 60, and 90 and; ii) oral vitamin D 2000 IU/daily for 4 months (from Day 1 through Day 120)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will be assigned to receive i) three (3) intralymphatic injections of Placebo for Diamyd (GAD-alum) on Days 30, 60, and 90 and; ii) oral Placebo for vitamin D once a day for 4 months (from Day 1 through Day 120)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GAD-alum</intervention_name>
    <description>Alhydrogel®-formulated recombinant human glutamic acid decarboxylase (rhGAD)</description>
    <arm_group_label>Active arm</arm_group_label>
    <other_name>Diamyd</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>Oil suspension of Vitamin D</description>
    <arm_group_label>Active arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo for Diamyd (GAD-alum)</intervention_name>
    <description>Alhydrogel® only</description>
    <arm_group_label>Placebo arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo for Vitamin D</intervention_name>
    <description>Placebo oil suspension for Vitamin D</description>
    <arm_group_label>Placebo arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Informed consent given by patients and/or patient's parent(s) or legal acceptable
             representative(s) (guardian(s)) according to national regulations

          2. T1D according to the ADA classification diagnosed ≤6 months at the time of screening

          3. Age: ≥12 and &lt;25 years old

          4. Fasting C-peptide ≥0.12 nmol/L (0.36 ng/ml) on at least one occasion (maximum 2 tests
             on different days within a period of 2 weeks)

          5. Positive for GAD65A but &lt; 50 000 IU/ml

          6. Females must agree to avoid pregnancy and have a negative urine pregnancy test.
             Patients of childbearing potential must agree to use adequate contraception, until one
             (1) year after the last administration of Diamyd. Adequate contraception is as
             follows:

        For females of childbearing potential:

          1. oral (except low‐dose gestagen (lynestrenol and norestisteron)), injectable, or
             implanted hormonal contraceptives

          2. combined (estrogen and progestogen containing)

          3. oral, intravaginal or transdermal progesterone hormonal contraception associated with
             inhibition of ovulation

          4. intrauterine device

          5. intrauterine hormone-releasing system (for example, progestin‐releasing coil)

          6. bilateral tubal occlusion

          7. vasectomized male (with appropriate post vasectomy documentation of the absence of
             sperm in the ejaculate)

          8. male partner using condom

          9. abstinence from heterosexual intercourse

        For males of childbearing potential:

          1. condom (male)

          2. abstinence from heterosexual intercourse

        Exclusion Criteria:

          1. Previous or current treatment with immunosuppressant therapy (although topical or
             inhaled steroids are accepted)

          2. Continuous treatment with anti-inflammatory drug (sporadic treatment e.g. because of
             headache or in connection with fever a few days will be accepted)

          3. Treatment with any oral or injected anti-diabetic medications other than insulin

          4. A history of anemia or significantly abnormal hematology results at screening

          5. A history of epilepsy, head trauma or cerebrovascular accident, or clinical features
             of continuous motor unit activity in proximal muscles

          6. Clinically significant history of acute reaction to vaccines or other drugs in the
             past

          7. Treatment with any vaccine, including influenza vaccine, within 4 months prior to
             planned first study drug dose or planned treatment with any vaccine up to 4 months
             after the last injection with study drug.

          8. Participation in other clinical trials with a new chemical entity within the previous
             3 months

          9. Inability or unwillingness to comply with the provisions of this protocol

         10. A history of alcohol or drug abuse

         11. A significant illness other than diabetes within 2 weeks prior to first dosing

         12. Known HIV or hepatitis

         13. Females who are lactating or pregnant (the possibility of pregnancy must be excluded
             by urine βHCG on-site within 24 hours prior to the Diamyd/placebo treatment)

         14. Presence of associated serious disease or condition, including active skin infections
             that preclude intralymphatic injection, which in the opinion of the investigator makes
             the patient non-eligible for the study

         15. Deemed by the investigator not being able to follow instructions and/or follow the
             study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>24 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johnny Ludvigsson, MD, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitetssjukhuset i Linköping</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Johnny Ludvigsson, MD, Prof</last_name>
    <phone>+46 13 28 68 54</phone>
    <email>johnny.ludvigsson@regionostergotland.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Diabetes Centre, Institute of Clinical and Experimental Medicine</name>
      <address>
        <city>Praha</city>
        <zip>14021</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Department of Paediatrics, University Hospital Motol</name>
      <address>
        <city>Praha</city>
        <zip>15006</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Adult and Pediatrics Endocrinology and Diabetology, Hospital Universitario Cruces</name>
      <address>
        <city>Barakaldo</city>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Adult Endocrinology and Diabetology, Hospital vall D' Hebrón</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pediatrics Endocrinology and Diabetology, Hospital Vall D'Hebrón</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Adult Endocrinology and Diabetology, Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pediatrics Endocrinology and Diabetology, Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Adult Endocrinology and Diabetology, Hospital Carlos Haya</name>
      <address>
        <city>Málaga</city>
        <zip>29009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pediatrics Endocrinology and Diabetology, Hospital Materno-Ifantil</name>
      <address>
        <city>Málaga</city>
        <zip>29011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Adult Endocrinology and Diabetology, Hospital Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pediatrics Endocrinology and Diabetology, Hospital Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Adult and Pediatrics Endocrinology and Diabetology, Hospital Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Barn- och Ungdomskliniken, Universitetssjukhuset</name>
      <address>
        <city>Linköping</city>
        <zip>58185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Endokrinmedicinska kliniken. Universitetssjukhuset</name>
      <address>
        <city>Linköping</city>
        <zip>58185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Barn-och Ungdomsmedicinmottagningen and Endokrinmottagningen, Skånes Universitetssjukhus</name>
      <address>
        <city>Malmö</city>
        <zip>20502</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Barn- och ungdomskliniken, Uddevalla Sjukhus</name>
      <address>
        <city>Uddevalla</city>
        <zip>45180</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Diabetesmottagningen, Uddevalla Sjukhus</name>
      <address>
        <city>Uddevalla</city>
        <zip>45180</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Barnmottagningen, Norrlands Universitetssjukhus</name>
      <address>
        <city>Umeå</city>
        <zip>901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Spain</country>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>http://www.diagnode-2.com</url>
    <description>Information regarding the clinical trial</description>
  </link>
  <reference>
    <citation>Ludvigsson J, Wahlberg J, Casas R. Intralymphatic Injection of Autoantigen in Type 1 Diabetes. N Engl J Med. 2017 Feb 16;376(7):697-699. doi: 10.1056/NEJMc1616343. Erratum in: N Engl J Med. 2017 Jul 27;377(4):405.</citation>
    <PMID>28199812</PMID>
  </reference>
  <reference>
    <citation>Ludvigsson J, Tavira B, Casas R. More on Intralymphatic Injection of Autoantigen in Type 1 Diabetes. N Engl J Med. 2017 Jul 27;377(4):403-5. doi: 10.1056/NEJMc1703468.</citation>
    <PMID>28745988</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2017</study_first_submitted>
  <study_first_submitted_qc>November 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diamyd</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Juvenile Diabetes</keyword>
  <keyword>Diabetes Type 1</keyword>
  <keyword>Type 1 Diabetes</keyword>
  <keyword>Autoimmune Diabetes</keyword>
  <keyword>Insulin Dependent Diabetes</keyword>
  <keyword>Type 1 Diabetes Mellitus</keyword>
  <keyword>rhGAD65</keyword>
  <keyword>GAD65</keyword>
  <keyword>GAD-Alum</keyword>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Diabetes Mellitus Type 1</keyword>
  <keyword>Glucose Metabolism Disorders</keyword>
  <keyword>Metabolic Diseases</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Vitamins</keyword>
  <keyword>Micronutrients</keyword>
  <keyword>Cholecalciferol</keyword>
  <keyword>Ergocalciferols</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Glucose Metabolism Disorders</mesh_term>
    <mesh_term>Immune System Diseases</mesh_term>
    <mesh_term>Endocrine System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Aluminum sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

